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Summary
Pseudohypoparathyroidism(PHP)isaheterogeneousgroupofrareendocrinedisorderscharacterisedbynormalrenal
functionandrenalresistancetotheactionoftheparathyroidhormone.Type1A(PHP1A),whichisthemostcommon
variant,alsoincludedevelopmentalandskeletaldefectsnamedasAlbrighthereditaryosteodystrophy(AHO).Wepresent
twocases,a54-anda33-year-oldmalediagnosedwithPHPwhowerereferredtousforpersistentlyhighlevelsofserum
calcitonin.AHOandmultinodulargoitrewerepresentinthe54-year-oldmale,whilethesecondpatientwasfreeofskeletal
deformitiesandhisthyroidglandwasofnormalsizeandwithoutnodularappearance.WeperformedGNASmolecular
analysis(methylationstatusandcopynumberanalysisbyMS-MLPA)ingenomicDNAsamplesforbothpatients.The
analysisrevealedanovelmissensevariantc.131T>Gp.(Leu44Pro)affectingGNASexon1,inthepatientwiththeclinical
diagnosisofPHP1A.Thisaminoacidchangeappearstobeinaccordancewiththeclinicaldiagnosisofthepatient.The
genomicDNAanalysisofthesecondpatientrevealedthepresenceoftherecurrent3-kbdeletionaffectingtheimprinting
controlregionlocalisedintheSTX16regionassociatedwiththelossofmethylation(LOM)attheGNASA/Bdifferentially
methylatedregionandconsistentwiththediagnosisofanautosomaldominantformofPHPtype1B(PHP1B).In
conclusion,hypercalcitoninaemiamaybeencounteredinPHP1AandPHP1Bevenintheabsenceofthyroidpathology.
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Learning points:
•• Wedescribeanovelmissensevariantc.131T>Gp.(Leu44Pro)affectingGNASexon1asthecauseofPHP1A.
•• HypercalcitoninaemiainPHP1Aisconsideredanassociatedresistancetocalcitonin,assuggestedbythe
generalisedimpairmentofGsα-mediated hormone signalling.GNASmethylationdefects,asintypePHP1B,without
thyroid pathology can also present with hypercalcitoninaemia.
Background
Pseudohypoparathyroidism (PHP) is a heterogeneous 
group of rare endocrine disorders characterised by normal 
renal function and resistance to the renal action of 
parathyroid hormone. Inactivating PTH/PTHrp signalling 
disorders (iPPSD) has been recently suggested, although 
not widely accepted, as a term encompassing all disorders 
related to this pathway (1).
The genetic background of the disease includes 
mutations and/or epigenetic changes at the complex 
GNAS gene on chromosome 20q13.3 that undergoes 
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parent-specific methylation changes at several sites. 
GNAS gene encodes alpha subunit of the stimulatory 
guanine nucleotide (Gsα) part of the signalling pathway of 
G-proteins-coupled receptors (GPCRs) and splice variants 
as well as an antisense transcript. Because of the much 
reduced paternal Gsα expression in certain tissues, such as 
the proximal renal tubules, thyroid and pituitary, there is 
little or no Gsα protein in the presence of maternal GNAS 
mutations. Furthermore, since a wide variety of hormonal 
peptides such as GHRH, TSH, FSH, LH or calcitonin (CT) 
act through GPCRs in different tissues, it is clear that 
patients with PHP may present with additional hormone 
dysfunctions.
Heterozygous maternal deletions within the STX16 
gene, which are associated with loss of mutation (LOM) 
at exon A/B also reduce Gsα expression, thus leading to 
hormonal resistance. Other genes that may be involved in 
this group of diseases are PRKAR1A and PDE4D (2).
As there is considerable variability in tissue 
responsiveness to Gsα protein deficiency, mainly due 
to differences in the quantity of cAMP that is necessary 
to activate the physiological responses in each tissue or 
absence of imprinting in target tissues, other hormones 
such as ACTH and vasopressin that also stimulate Gsα 
protein are not usually impaired (3), although ACTH 
resistance has been described before in PHP type 1 (4).
There are several variants of PHP, including type 
1A (PHPIA), type 1B (PHP1B), type 1C (PHP1C), type 2 
(PHP2) and pseudopseudohypoparathyroidism (PPHP). 
The phenotype of PHP1A, which is the most commonly 
found variant (5), and PHP1C include multiple hormone 
resistance and skeletal defects such as short stature, 
obesity, round face, subcutaneous ossifications and 
brachydactyly, collectively named as Albright's hereditary 
osteodystrophy (AHO) (6). PHP1B is pathogenetically 
linked to imprinting methylation defects at the GNAS 
locus resulting in lack of expression of the maternal allele 
almost exclusively in the renal tissue (7) and usually 
lack AHO, but may present with additional hormone 
dysfunctions, most frequently TSH resistance (8).
Pseudopseudohypoparathyroidism, on the other 
hand, is a clinical entity characterised by AHO phenotype 
without hormone resistance and is linked to GNAS 
mutations in the paternally inherited allele (7).
Hypercalcitoninaemia has been sporadically described 
in patients with PHP1A and IB (9, 10, 11), but the exact 
pathogenetic mechanism and its relation to the future 
development of medullary thyroid carcinoma (MTC) 
remain unknown. We present two cases of PHP with 
distinct phenotypes that were referred to our outpatient 
endocrine clinic for further investigation of their 
persistently high levels of serum calcitonin.
Case presentation
Case 1 was a 54-year-old male complaining of weakness, 
fatigue and periodic headache. His general practitioner 
asked for consultancy from an endocrinologist seeking 
for further investigation of his hypercalcitoninaemia on 
the ground of multinodular goitre (calcitonin >100 pg/mL 
in repeated measurements). The physical examination 
revealed an obese person (BMI: 39.7) with short stature 
(height: 165 cm) (Table 1), round face, stocky appearance 
with notable facial puffiness and brachydactyly of hands 
and feet. There was no report of his physical appearance 
up to the day he visited our department. An epicranial 
subcutaneous ossification was removed in the fronto-
parietal area of the head 6  years before. At that time, 
he was found to have asymptomatic hypocalcaemia 
and started treatment with active vitamin D analogues 
(1.0 μg of 1a-OH vitamin D) and oral calcium carbonate 
2 g/day, which he continued up to the day we examined 
the patient. Ten years before, he was diagnosed with 
chronic lymphocytic thyroiditis (Hashimoto’s) and 
multinodular goitre and he was treated since then with 
225 μg of levothyroxine. His blood pressure was normal 
(125/82 mmHg) and the pulse rate was 78/min. The tendon 
reflexes were normal. The X-rays of the hands revealed 
shortening of the metacarpals with epiphyseal widening, 
conical configuration of the phalangeal heads, osteopenic 
appearance, as well as stenosis of the phalangeal joint 
space and hardening of the joint surfaces.
His laboratory workup revealed hypocalcaemia and 
phosphate levels slightly above normal with elevated 
serum PTH and calcitonin levels (Table 2). Based on the 
laboratory results and his clinical appearance, we diagnosed 
PHP1A with AHO. To confirm our diagnosis we performed 
the Howard–Ellsworth test with s.c. administration of 
recombinant 1-34 N-terminal fragment of endogenous 
human parathyroid hormone (INN-teriparatide, Forsteo, 
Pharmaserve-Lilly, Inc). Administration of 20 μg of 
INN-teriparatide did not change urine cAMP and PO4 
levels analysed on samples voided every 30 min for 
3 h post injection (Fig.  1). Urinary cAMP is measured 
using an ELISA (Cayman Chemicals), according to the 
manufacturer’s instructions. The standard curve range for 
this assay is 0.078–10 pmol/mL, with a sensitivity (80% B/
B0) of 0.1 pmol/mL.
Case 2 was a 33-year-old male complaining of 
generalised muscular weakness, pain and tetany (twitches 
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of the quadriceps) while lying down and was referred to us 
for his persistently high levels of calcitonin in the absence 
of thyroid pathology (Table  1). Laboratory workup 
revealed severe hypocalcaemia, hyperphosphataemia, 
high levels of serum PTH and calcitonin (Table  2). The 
patient suffered from Gilbert syndrome, bilateral inguinal 
hernia and mild scoliosis, but his physical appearance was 
otherwise normal without signs of AHO. Administration 
of 20 μg of INN-teriparatide also did not change urine 
cAMP and PO4 levels (Fig. 1).
Table 1 Clinical presentation of cases.
Case 1 Case 2
Age 54 33
Bodyweight(kg) 108 78
Height(cm) 165 177
BMI 39.7 24.9
AHO Present Absent
Main symptoms Weakness,fatigue Weakness,tetany
Medical record Epicranialsubcutaneousossification Gilbertsyndrome,bilateralinguinalhernia,
mild scoliosis
Thyroid ultrasound Multinodular goitre Normal morphology
Familyhistoryofpseudohypoparathyroidism Absent Absent
Brown tumours Absent Absent
Historyofbasicgangliacalcification/seizures Absent Absent
Table 2 Laboratoryworkup.
Parameters Case 1 Case 2 Normal values
Bloodglucose(mg/dL) 102 89 60–100
Serumcreatinine(mg/dL) 1.0 0.8 0.8–1.4
Totalcholesterol(mg/dL) 120 138 <200
HDLcholesterol(mg/dL) 25 34 >40
Triglycerides(mg/dL) 113 54 <150
LDLcholesterol(mg/dL) 75 109 <100
Hct(%) 43 48.4 42–52
WBC 7.500 4300 4000–10,000
BUN(mg/dL) 29 7–22
SGOT(U/L) 40 21 <40
SGPT(U/L) 48 23 <40
Uricacid(mg/dL) 7.5* 2.8 3.0–7.0
Serumcalcium(mg/dL) 7.4* 6.2* 8.7–10.3
Serumphosphorus(mg/dL) 4.7* 5.9* 2.5–4.5
Alkalinephosphatase(U/L) 60 77 35–100
SerumNa+(mEq/L) 142 142 135–145
SerumK+(mEq/L) 4.1 4.0 3.5–5.0
Albumin(g/dL) 3.5 4.6 3.5–5.0
Urineexam Normal
Urinecalcium(mg/24 h) 31.2* 42.90 100–300
Urinecreatinine(mg/24 h) 1605 1204 500–2000
TSH(μU/mL) 3.4 2.470 0.4–5.0
Anti-TGab 30.70*
Anti-TPO ab >1300*
Serumcalcitonin(pg/mL) 114* 92* <13.8
PTH(pg/mL) 133* 442.60* 11.0–54.0
FSH(IU/L) 8.57 10.3 1–12
LH(IU/L) 3.84 8.0 1.5–9.3
Totaltestosterone(ng/dL) 210 669 193–740
Serumcortisol(morning-fast)(μg/dL) 5.54 11.50 5.0–25
PlasmaACTH(pg/mL) 31.4 42 6.0–76.0
*Indicate abnormal values.
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Investigation
We performed GNAS molecular analysis (methylation 
status and copy number analysis by MS-MLPA) in genomic 
DNA samples for both patients as previously described 
(12). Case 1 revealed a novel missense variant c.131T>G 
p.(Leu44Pro) affecting GNAS exon 1 which encodes for 
an altered protein and is likely responsible for the clinical 
phenotype presented by the patient.
Case 2 revealed the presence of the recurrent 3-kb 
deletion affecting the imprinting control region localised 
in the STX16 region associated with the LOM at the GNAS 
A/B differentially methylated region and consistent with 
the diagnosis of an autosomal dominant form of PHP1B. 
None of our patients had a family history of biochemical 
or phenotypic abnormalities consistent with the diagnosis 
of PHP, but we were not able to perform DNA testing for 
parents.
Evaluating further persistent hypercalcitoninaemia 
in our patients, we performed a neck ultrasonography in 
both cases.
Case 1 had a thyroid gland with normal size and 
multiple spongiform nodules with smooth outline. The 
size of the larger nodule was 1.5 × 0.75 cm with poor 
peripheral vasculature near isthmus. Few normal lymph 
nodes were also reported. Fine-needle aspiration was 
negative for malignant features in the larger nodule. Since 
it is currently unknown whether patients with PHP and 
hypercalcitoninaemia are at increased risk of medullary 
thyroid cancer and upon our patients’ request, a total 
thyroidectomy was followed that showed no signs of 
malignancy.
Case 2 had a normal thyroid gland in terms of size and 
appearance, without evidence of nodules, and therefore, 
we did not recommend prophylactic thyroidectomy. 
In both of our patients, other pathological conditions 
known to induce hypercalcitoninaemia such as chronic 
renal failure, neuroendocrine tumours originating from 
neural crest cells, hypergastrinaemia and use of proton 
pump inhibitors were excluded. In case 1, we also 
performed administration of pentagastrin 0.5 μg/kg before 
total thyroidectomy that increased further calcitonin 
levels despite hypocalcaemia (baseline: 114 pg/mL max at 
2 min: 205 pg/mL).
There was no evidence of brown tumours in any of 
our patients.
Treatment
Our first patient (case 1) continued to receive active 
alfacalcidol 1.0 μg, oral calcium carbonate 2 g/day and 
levothyroxine 225 μg.
Case 2 started treatment with alfacalcidol 2 μg and 
calcium carbonate (2 g/day) with immediate alleviation of 
symptoms and progressive normalisation of biochemical 
parameters.
Outcome and follow-up
In the follow-up examination, both cases maintained 
serum calcium levels within the low normal reference 
range (case 1: 8.6 mg/dL, case 2: 8.4 mg/dL) without 
clinical symptomatology of hypocalcaemia. Calcitonin 
levels remained elevated in case 2 (102 pg/mL) and were 
undetectable 1 month post thyroidectomy in case 1.
Discussion
We report here two cases with PHP, PHP1A and PHP1B 
that developed hypercalcitoninaemia during the course 
of their disease.
Hypercalcitoninaemia is considered a sensitive 
marker for MTC, although it presents low specificity for 
this tumour. Several other physiologic and pathologic 
conditions have been associated with increased levels 
of calcitonin such as neuroendocrine tumours, renal 
insufficiency, papillary and follicular thyroid carcinomas, 
goitre, stress and pregnancy, and as in PHP, patients should 
Figure 1
ResultsoftheHowardEllsworthtest.(A)UrinarycAMPlevelsand(B)
Urinary phosphate levels.
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have a regular follow-up in order to avoid unnecessary 
thyroidectomy.
Hypercalcitoninaemia has been described before in a 
limited number of PHP1A cases, attributed to an associated 
resistance to calcitonin, as suggested by the generalised 
impairment of Gsα-mediated hormone signal transduction 
in this disease. We present a genetically confirmed case of 
PHP1A harbouring a novel mutation in GNAS gene that 
presented with high levels of calcitonin both at baseline 
and after pentagastrin stimulation. We also report high 
calcitonin levels in a patient with genetically confirmed 
PHP1B, linked with GNAS methylation defects without 
evidence of any other endocrinopathies and with normal 
thyroid ultrasound.
Since other causes of hypercalcitoninaemia such 
as MTC were ruled out, the exact mechanism of this 
manifestation and its clinical relevance with C cell 
dysfunction remain unanswered.
Despite the remarkable progress that has been 
done in the field of PTHR signalling, many of the 
molecular mechanisms underlying hormone resistance 
and imprinting defects in PHP remain incompletely 
understood. In future, detailed clinical and 
molecular characterisation will increase our knowledge 
about this complex gene and this unique form of the 
disorder.
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